Cardiovascular disease (CVD) is projected to be the leading cause of death in India by the year 2020 and alarmingly 50 % of these deaths are projected to occur among young and middle aged individuals. High density lipoprotein (HDL) has emerged as an important predictor of CAD. Low HDL is a widely prevalent risk factor among Indians. The athero-protective effect of HDL is primarily due to its role in reverse cholesterol transport (RCT). RCT is a complex pathway involving transport proteins, modifying enzymes and cell surface receptors. Cholesterol ester transfer protein (CETP) plays a key role in RCT by promoting exchange of cholesteryl esters from HDL to apo B containing lipoproteins. Taq1B polymorphism resulting from mutation in 277 th nucleotide in the first intron of CETP gene results in decreased CETP and increased HDL levels. We looked ar prevalence of Taq1B polymorphism in CETP gene in an industrial population from North India and looked at its association with other cardiovascular risk factors. 1000 employees/family members of an industry located in Ghaziabad were recruited for the study. We had 250 subjects (125 males and 125 females) from each age decile from 20-59. Blood was collected in fasting state and Taq1B polymorphism was assessed by PCR-RFLP. The other cardiovascular risk factors studied included lipids, apolipoprotein A1, apolipoprotein B, apolipoprotein E, hsCRP, lipoprotein (a), LDL subfraction and insulin. The Taq1B genotype frequencies of B1B1, B1B2 and B2B2 were 26%, 54% and 20% respectively. B1B1 homozygote was associated with lower HDL in males in the 30-39 age group. Gender and age specific differences were also observed in the association of genotypes with other cardiovascular risk factors. Subjects in the 30-39 age group with B1B1 genotype had higher Apolipoprotein B, Cholesterol, triglycerides and TC/HDL. We found B1B1 genotype in a substantial proportion of the cohort and the Taq1B polymorphism was associated with HDL and other cardiovascular risk factors in an age and gender specific manner.
Cell adhesion molecules (CAMs) are shown to be involved in the developmental course of atherosclerosis at vascular endothelial wall. This study was undertaken to analyse the association of soluble levels of CAMs with hypertension and coronary artery disease (CAD).Soluble (s) levels of Intercellular CAM-1 (1CAM-1). vascular C'AM-1 (VCAM-1). endothelial (E)-selectin, platelet (P)-selectin and platelet endothelial CAM-1 (PECAM-1) were estimated from serum by ELISA. The study population included healthy individuals (n=151) and non-diabetic freshly diagnosed hypertensive (FH) subjects (n=59) with no secondary cause. CAD group included angiographically verified non-diabetic CAD patients admitted at Sir H. N. Hospital and Research Centre (n=125). As compared to controls in FH subjects, there was significant rise in sEselectin of 56.25 (p = 0.001). sPECAM-1 of 24.6 (p = 0.039) and slCAM-1 of 18.85 (p = 0.002) and marginal increase in sP-selectin and sVCAM-1. Overall in CAD group, significant rise was seen in sEselectin of 69.11 (p = 0.001), followed by sVCAM-1 of 41.76 (p = 0.001), and sICAM-1 of 14.39 (p = 0.001) as compared to controls. There was no change in sP-selectin level and sPECAM-1 decreased significantly by 38.73 (p=0.001). Within CAD group there was no significant difference in soluble levels of CAMs according to the number of vessels affected or severity of the clinical presentation. However those with hypertension and dyslipidemia demonstrated significant rise only in sPECAM-1 of 48.05 (p = 0.001) as compared to normotensive and normolipemic CAD patients. sPECAM-1. a multifunctional cell adhesion molecule with important role in plaque formation and thrombosis was significantly} associated with CAD patients with hypertension and dyslipidemia. As compaired to controls , we observed maximum increase in SE-selectin in FH and CAD followed by sPECAM-1 in FH and sVCAM-1 in CAD.
Curriculum Vitae: Diagnosis and treatment of chronic heart failure is one of the major challenges of modern cardiology. Many of CHF patients are eithere underdiagnosed or misdiagnosed. CHF is a very serious disease with high mortality rate. It is very important to diagnose CHF patients in time and treat them appropriately. Recent studies have confirmed the clinical usefulness of NT-pro BNP and BNP assays in the management CHF patients. The results of these studies will be presented in the perspective of Evidence-Based Laboratory medicine. The accuracy, reliability and cost effectiveness of these NT-pro BNP and BNP have been confirmed. Diagnostic specificity and sensitivity of NT-pro BNP assays is much better than any other clinical information like echocardiography, these tests are better used in along with other physical and clinical examinations for better outcome.
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